VHL Polyclonal Antibody

Ab type

Primary antibody

Background

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Reactivity

Human, Rat, Mouse

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Immunogen

The antiserum was produced against synthesized peptide derived from the N-terminal region of human VHL. AA range:1-50

Storage Stability

-20°C for 1 year

Concentration

1 mg/ml

MolecularWeight_Da

synonyms

Von Hippel-Lindau disease tumor suppressor ;Protein G7;pVHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL